About
Montis Biosciences develops dual-mechanism antibodies targeting complement C1q to treat neuroinflammatory, autoimmune, neurodegenerative, and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and other conditions involving complement and macrophage activation.
Explore Montis Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.